Company Information
Santhera Pharmaceuticals Holding AG
Hammerstrasse 47
4410 Liestal
Suisse
+41 (0) 61 906 89 89
http://www.santhera.com
- CEO
- Dr. Klaus Schollmeier
- Investor Relations
- Thomas Staffelbach
Santhera is Swiss specialty pharmaceutical company focusing on the discovery, development and commercialization of innovative pharmaceuticals for the treatment of severe neuromuscular diseases. The Company addresses the high unmet medical need associated with these diseases where few, if any, effective therapies currently exist.
Trading Information
- Sector
- Health Care - 4500
- Regulatory Standard
- International Reporting Standard
- Security Number
- 2714864
- ISIN
- CH0027148649
- Symbol
- SANN
- Index member
- ???/???
Intermediaries
- Listing Agent
- Deutsche Bank AG
- Lead Bank
- Deutsche Bank AG
- Auditor
- Ernst & Young
Information on the Issue
| Security Details | |
|---|---|
| First Listing | 03.11.2006 |
| Class of Share | Action nominative |
| Nominal Value | 1.00 CHF |
| Total Shares outstanding (post issue; incl. Greenshore - if any) | 3099156 |
| Allocation Details | |
|---|---|
| Primary Shares | 983859 |
| Secondary Shares | n/a |
| Primary Greenshoe | 147579 |
| Secondary Greenshoe | n/a |
| Greenshoe Details | |
|---|---|
| Executed | yes |
| Ex-date | 24.11.2006 |
| Executed number of shares | 147579 |
| First Trading Day Details | |
|---|---|
| First Trading | 03.11.2006 |
| Price Range | 85.00 - 100.00 CHF |
| Issue Price | 90.00 CHF |
| First Open | 90.20 CHF |
| First Close | 90.75 CHF |
| Transaction size in Mio. (incl. executed Greenshoe) | 101.8 CHF |
| Market Capitalisation in Mio. (based on first closing price) | 281 CHF |
Financial Statement
| Number of Employees | 49 FTE Juni, 2006 |
| Net Revenues in Mio. | 0.8 CHF Half-year Report as per 30.06.2006 - not audited |
| Net Gain in Mio. | n/a |